Iryna Tymchenko
Current Organizations / Institutes
The organizations/institutes from the scholar's latest article
Iryna Tymchenko has a total of 22 co-authors. Here are the top co-authors by number of shared publications:
- Kateryna Marchenko-Tolsta
ПВНЗ «Київський медичний університет
4 shared publications - Sepideh Parchami Ghazaee
Kyiv Medical University, Kyiv, Ukraine
3 shared publications - Ella Gorova2 shared publications
Larysa Novykova
2 shared publications- Marharyta Zolotaikina
Kyiv Medical University, Ukraine
2 shared publications - Ihor Danyliuk1 shared publication
Latest Publications
- 3 September 2026
- Published by Publishing House Helvetica (Publications) in Fitoterapia
- No. 2,p. 66-81
Phytotherapy targeting immunosenescence: mechanistic perspectives for healthy ageing (mini-review)
- 3 September 2026
- Published by Publishing House Helvetica (Publications) in Fitoterapia
- No. 2,p. 66-81
Phytotherapy targeting immunosenescence: mechanistic perspectives for healthy ageing (mini-review)
- Open Access
- 10 April 2026
- Published by LLC Information and Research Center Likarska Sprava in Likars'ka Sprava
- No. 2,p. 69–75
Pharmacological mechanisms and therapeutic implications of herbal immunomodulators (mini-review)
Introduction. Immunomodulatory medicinal plants have been extensively investigated in vitro, in animal models, and in human studies. Aromatic and essential oil–containing species, including Laurus nobilis, Nigella sativa, Withania somnifera, Echinacea purpurea, and Andrographis paniculata, comprise bioactive phytochemicals such as terpenoids, flavonoids, and phenolic compounds that influence both innate and adaptive immune responses. Aim of the study. This review aimed to provide a translational analysis of mechanistic, preclinical, and clinical evidence supporting their immunomodulatory potential. Methodology. A comprehensive literature search was conducted using PubMed, Scopus, and Web of Science, focusing on experimental and human studies reporting immunological outcomes. Discussion. Preclinical investigations demonstrate that plant-derived compounds modulate macrophage activation, cytokine expression, lymphocyte proliferation, and natural killer (NK) cell activity. For example, andrographolide influences T-cell signalling and cytokine production, while thymoquinone enhances NK cell cytotoxicity and regulates Th1/Th2 balance. Translational human studies report increased lymphocyte counts and cytokine levels following supplementation with standardised extracts. Randomised controlled trials further indicate that Withania somnifera enhances immunoglobulins, T helper cells, and NK cell activity. Echinacea purpurea increases NK cytotoxicity and cytokine production, and Allium-based formulations reduce the incidence and severity of respiratory infections in older adults. From a pharmacological perspective, these plants act as multi-target agents modulating signalling cascades and gene expression. However, variability in extract standardisation, dosage regimens, and bioavailability contributes to heterogeneity in clinical outcomes. Conclusion. Overall, medicinal plants demonstrate regulatory rather than purely stimulatory immune effects, supporting their potential role in integrative immunotherapy. Further large-scale, well-controlled trials using standardised preparations are required to strengthen clinical translation.
- 10 April 2026
- Published by LLC Information and Research Center Likarska Sprava in Likars'ka Sprava
- No. 2,p. 69–75
Open AccessPharmacological mechanisms and therapeutic implications of herbal immunomodulators (mini-review)
Introduction. Immunomodulatory medicinal plants have been extensively investigated in vitro, in animal models, and in human studies. Aromatic and essential oil–containing species, including Laurus nobilis, Nigella sativa, Withania somnifera, Echinacea purpurea, and Andrographis paniculata, comprise bioactive phytochemicals such as terpenoids, flavonoids, and phenolic compounds that influence both innate and adaptive immune responses. Aim of the study. This review aimed to provide a translational analysis of mechanistic, preclinical, and clinical evidence supporting their immunomodulatory potential. Methodology. A comprehensive literature search was conducted using PubMed, Scopus, and Web of Science, focusing on experimental and human studies reporting immunological outcomes. Discussion. Preclinical investigations demonstrate that plant-derived compounds modulate macrophage activation, cytokine expression, lymphocyte proliferation, and natural killer (NK) cell activity. For example, andrographolide influences T-cell signalling and cytokine production, while thymoquinone enhances NK cell cytotoxicity and regulates Th1/Th2 balance. Translational human studies report increased lymphocyte counts and cytokine levels following supplementation with standardised extracts. Randomised controlled trials further indicate that Withania somnifera enhances immunoglobulins, T helper cells, and NK cell activity. Echinacea purpurea increases NK cytotoxicity and cytokine production, and Allium-based formulations reduce the incidence and severity of respiratory infections in older adults. From a pharmacological perspective, these plants act as multi-target agents modulating signalling cascades and gene expression. However, variability in extract standardisation, dosage regimens, and bioavailability contributes to heterogeneity in clinical outcomes. Conclusion. Overall, medicinal plants demonstrate regulatory rather than purely stimulatory immune effects, supporting their potential role in integrative immunotherapy. Further large-scale, well-controlled trials using standardised preparations are required to strengthen clinical translation.
- Open Access
- 3 April 2026
- Published by Poltava State Medical University (PSMU) in Актуальні проблеми сучасної медицини: Вісник Української медичної стоматологічної академії
- Vol. 26 (1) , 270-275
OPTIMIZING THE USE OF NONSTEROIDAL ANTI-INFLAMMATORY DRUGS (NSAIDS) THROUGH THE INTEGRATION OF PHARMACOGENETIC AND RACIAL–ETHNIC DATA: FROM THE IDENTIFICATION OF GENETIC AND POPULATION FACTORS TO THE IMPROVEMENT OF THERAPEUTIC ALGORITHMS
Introduction. A pressing issue in contemporary medicine is the optimization of nonsteroidal anti-inflammatory drug (NSAID) use to enhance therapeutic efficacy while minimizing the risk of adverse effects. Increasing evidence indicates that these outcomes are influenced by population genetic and ethnic differences associated with variations in allele frequencies. The aim of the study was to identify the main approaches to optimizing the use of nonsteroidal anti-inflammatory drugs by integrating pharmacogenetic data and racial and ethnic characteristics of patients. Materials and methods. This study was based on an analysis of publications selected from the PubMed, Scopus, Web of Science, and Google Scholar scientific databases for the period from 2019 to 2025. The study used methods of comparative analysis and synthesis, systematization, and generalization. Results. Pharmacogenetics indicates that genetic variations affecting enzymes responsible for the metabolism of nonsteroidal anti-inflammatory drugs (NSAIDs) can influence drug concentration, duration of action, and the risk of adverse effects. The distribution of key pharmacogenetic variants across different ethnic populations has been characterized, providing a basis for the development of personalized approaches to NSAID therapy. The present study demonstrates that optimizing NSAID use requires the integration of pharmacogenetic data with racial and ethnic characteristics. Genetic studies have identified polymorphisms in genes such as CYP2C9, CYP2C8, ABCB1, SLCO1B1, PTGS1, and PTGS2, which contribute to interindividual variability in drug metabolism, bioavailability, and susceptibility to adverse reactions. The CYP2C92* allele is most prevalent in Middle Eastern and European populations and is rare in sub-Saharan African and East Asian populations. In contrast, the highest frequency of the CYP2C93* allele has been observed in Asian populations, followed by those in Southern Europe. These interethnic differences necessitate the adaptation of therapeutic algorithms and support the transition from standardized to personalized treatment strategies. The implementation of individual genotyping, expansion of pharmacogenetic testing panels, and the use of population-based data in the absence of individual testing may reduce the incidence of adverse effects and improve therapeutic efficacy. Conclusions. Ethnic variability in genetic markers significantly influences the efficacy and safety of NSAID therapy. The integration of pharmacogenetic data with ethnic variability facilitates the transition toward personalized medicine and enhances the safe and effective use of NSAIDs.
- 3 April 2026
- Published by Poltava State Medical University (PSMU) in Актуальні проблеми сучасної медицини: Вісник Української медичної стоматологічної академії
- Vol. 26 (1) , 270-275
Open AccessOPTIMIZING THE USE OF NONSTEROIDAL ANTI-INFLAMMATORY DRUGS (NSAIDS) THROUGH THE INTEGRATION OF PHARMACOGENETIC AND RACIAL–ETHNIC DATA: FROM THE IDENTIFICATION OF GENETIC AND POPULATION FACTORS TO THE IMPROVEMENT OF THERAPEUTIC ALGORITHMS
Introduction. A pressing issue in contemporary medicine is the optimization of nonsteroidal anti-inflammatory drug (NSAID) use to enhance therapeutic efficacy while minimizing the risk of adverse effects. Increasing evidence indicates that these outcomes are influenced by population genetic and ethnic differences associated with variations in allele frequencies. The aim of the study was to identify the main approaches to optimizing the use of nonsteroidal anti-inflammatory drugs by integrating pharmacogenetic data and racial and ethnic characteristics of patients. Materials and methods. This study was based on an analysis of publications selected from the PubMed, Scopus, Web of Science, and Google Scholar scientific databases for the period from 2019 to 2025. The study used methods of comparative analysis and synthesis, systematization, and generalization. Results. Pharmacogenetics indicates that genetic variations affecting enzymes responsible for the metabolism of nonsteroidal anti-inflammatory drugs (NSAIDs) can influence drug concentration, duration of action, and the risk of adverse effects. The distribution of key pharmacogenetic variants across different ethnic populations has been characterized, providing a basis for the development of personalized approaches to NSAID therapy. The present study demonstrates that optimizing NSAID use requires the integration of pharmacogenetic data with racial and ethnic characteristics. Genetic studies have identified polymorphisms in genes such as CYP2C9, CYP2C8, ABCB1, SLCO1B1, PTGS1, and PTGS2, which contribute to interindividual variability in drug metabolism, bioavailability, and susceptibility to adverse reactions. The CYP2C92* allele is most prevalent in Middle Eastern and European populations and is rare in sub-Saharan African and East Asian populations. In contrast, the highest frequency of the CYP2C93* allele has been observed in Asian populations, followed by those in Southern Europe. These interethnic differences necessitate the adaptation of therapeutic algorithms and support the transition from standardized to personalized treatment strategies. The implementation of individual genotyping, expansion of pharmacogenetic testing panels, and the use of population-based data in the absence of individual testing may reduce the incidence of adverse effects and improve therapeutic efficacy. Conclusions. Ethnic variability in genetic markers significantly influences the efficacy and safety of NSAID therapy. The integration of pharmacogenetic data with ethnic variability facilitates the transition toward personalized medicine and enhances the safe and effective use of NSAIDs.
- Open Access
- 20 February 2026
- Published by European Scientific Platform (Publications) in Grail of Science
- No. 62,p. 1344-1349
INTEGRATING GERMLINE TRANSPORTER PHARMACOGENOMICS AND SOMATIC MUTATIONS IN CANCER THERAPY
This review examines the critical role of genetic variation, including both germline and somatic mutations, in shaping cancer therapy outcomes. Using population-based data from 185 countries, it highlights the growing global burden of cancer, projecting a threefold increase in incidence and mortality in low-Human Development Index (HDI) countries by 2050, while high-HDI countries are expected to experience smaller increases. Lung cancer is identified as the leading cause of cancer incidence and death and is projected to remain so, accounting for over 10% of cases and fatalities. The study emphasizes the significance of drug transporter genes, particularly those in the ATP-binding cassette (ABC) families, in regulating drug absorption, distribution, metabolism, and excretion, thereby influencing both efficacy and toxicity. Clinical evidence demonstrates that polymorphisms in ABCB1, ABCC1, ABCC2, and ABCG2 affect patient responses to targeted therapies, such as osimertinib and abemaciclib, as well as conventional chemotherapy. Somatic variants, including the BCR-ABL fusion in chronic myeloid leukemia and mutations in EGFR, ALK, BRAF, and MEK, play a central role in tumor progression, drug resistance, and therapy sensitivity, underscoring their relevance in precision oncology. The review advocates integrating both germline and somatic pharmacogenomic testing into routine clinical workflows, developing evidence-based guidelines for actionable variants, and implementing decision-support tools for interpreting complex genetic data. It highlights the need for diverse population studies to ensure global applicability. Advanced molecular approaches, including circulating tumor DNA and liquid biopsies, are recommended for dynamic tumor monitoring and adaptive therapy planning. Together, these strategies aim to optimize personalized cancer treatment, improve therapeutic outcomes, minimize adverse effects, and support the broader adoption of pharmacogenomic-guided oncology.
- 20 February 2026
- Published by European Scientific Platform (Publications) in Grail of Science
- No. 62,p. 1344-1349
Open AccessINTEGRATING GERMLINE TRANSPORTER PHARMACOGENOMICS AND SOMATIC MUTATIONS IN CANCER THERAPY
This review examines the critical role of genetic variation, including both germline and somatic mutations, in shaping cancer therapy outcomes. Using population-based data from 185 countries, it highlights the growing global burden of cancer, projecting a threefold increase in incidence and mortality in low-Human Development Index (HDI) countries by 2050, while high-HDI countries are expected to experience smaller increases. Lung cancer is identified as the leading cause of cancer incidence and death and is projected to remain so, accounting for over 10% of cases and fatalities. The study emphasizes the significance of drug transporter genes, particularly those in the ATP-binding cassette (ABC) families, in regulating drug absorption, distribution, metabolism, and excretion, thereby influencing both efficacy and toxicity. Clinical evidence demonstrates that polymorphisms in ABCB1, ABCC1, ABCC2, and ABCG2 affect patient responses to targeted therapies, such as osimertinib and abemaciclib, as well as conventional chemotherapy. Somatic variants, including the BCR-ABL fusion in chronic myeloid leukemia and mutations in EGFR, ALK, BRAF, and MEK, play a central role in tumor progression, drug resistance, and therapy sensitivity, underscoring their relevance in precision oncology. The review advocates integrating both germline and somatic pharmacogenomic testing into routine clinical workflows, developing evidence-based guidelines for actionable variants, and implementing decision-support tools for interpreting complex genetic data. It highlights the need for diverse population studies to ensure global applicability. Advanced molecular approaches, including circulating tumor DNA and liquid biopsies, are recommended for dynamic tumor monitoring and adaptive therapy planning. Together, these strategies aim to optimize personalized cancer treatment, improve therapeutic outcomes, minimize adverse effects, and support the broader adoption of pharmacogenomic-guided oncology.
- Open Access
- 12 July 2025
- Published by Revista Eletronica Politica e Gestao Educacional in Periferia
- p. e025017
The Importance of Scientific Integrity for the Improvement of University Level Learning
The study focuses on the concept of higher education development in terms of academic integrity. The article aims to analyze the role of technology in creating a unique text within scientific communication in the current information space. The functionality of scientific communication in higher education is substantiated. The trends in the development of modern models of scientific communication are highlighted. The specifics of innovative approaches to creating a unique scientific text are investigated. The problems of the life cycle of electronic resources and related risks are studied. The principles of the Bucharest Declaration on Ethical Values and Principles of Higher Education in the European Region are analyzed. The directions for improving scientific communication processes in higher education are defined. The article demonstrates that the development of the educational environment in the modern, globalized scientific field necessitates the optimization of specific requirements for creating a unique text based on the principles of originality and integrity.
- 12 July 2025
- Published by Revista Eletronica Politica e Gestao Educacional in Periferia
- p. e025017
Open Access The Importance of Scientific Integrity for the Improvement of University Level Learning
The study focuses on the concept of higher education development in terms of academic integrity. The article aims to analyze the role of technology in creating a unique text within scientific communication in the current information space. The functionality of scientific communication in higher education is substantiated. The trends in the development of modern models of scientific communication are highlighted. The specifics of innovative approaches to creating a unique scientific text are investigated. The problems of the life cycle of electronic resources and related risks are studied. The principles of the Bucharest Declaration on Ethical Values and Principles of Higher Education in the European Region are analyzed. The directions for improving scientific communication processes in higher education are defined. The article demonstrates that the development of the educational environment in the modern, globalized scientific field necessitates the optimization of specific requirements for creating a unique text based on the principles of originality and integrity.
- 1 January 2025
- Published by Publishing House Helvetica (Publications) in Fitoterapia
- No. 2,p. 64-74
Integrating pharmacogenetics into medical education: an updated systematic review of cross-sectional studies
- 1 January 2025
- Published by Publishing House Helvetica (Publications) in Fitoterapia
- No. 2,p. 64-74
Integrating pharmacogenetics into medical education: an updated systematic review of cross-sectional studies